BioNTech Projects $2.2–2.5B 2026 Revenue as Founders Plan Year-End Exit
BioNTech projected 2026 revenue of $2.2–2.5 billion, falling short of estimates as COVID-19 vaccine volumes decline and prompting a pivot to a multi-year oncology pipeline. Co-founders Uğur Şahin and Özlem Türeci will exit by end-2026 to launch a separate mRNA venture, contributing IP for a minority stake and royalties.
1. 2026 Revenue Guidance Miss
BioNTech set 2026 revenue guidance at $2.2–2.5 billion, below consensus as COVID-19 vaccine sales normalize. This outlook underscores the company’s shift toward long-term oncology assets to sustain growth beyond pandemic-era demand.
2. Founders Transition and New Venture
Co-founders and Chief Executive Officer Uğur Şahin and Chief Medical Officer Özlem Türeci will exit by the end of 2026 to launch an independent mRNA venture. BioNTech will transfer select intellectual property to the new firm in exchange for a minority equity stake, milestone payments and royalties.
3. Oncology Pivot and R&D Funding
The firm holds $17.2 billion in cash and securities and plans $2.4–2.7 billion in R&D for 2026, funding a push to advance its oncology pipeline. Executive leadership targets 15 Phase 3 clinical trials by year-end to accelerate late-stage program momentum.
4. Share Price Reaction and Investor Sentiment
Shares plunged approximately 18–21% on the day of the announcements as investors reevaluated near-term earnings and leadership continuity. The decline highlights mounting concern over funding intensive research while navigating the founders’ transition.